AI-powered point-of-care EEG platform for acute care seizure detection
Ceribell manufactures a portable, AI-driven EEG system for rapid seizure detection in ICUs and emergency departments. The company is sales-heavy (60 of 92 open roles) with minimal engineering headcount, indicating a market-expansion phase focused on hospital adoption rather than product R&D. Active projects center on launching new hospitals, expanding into adjacent departments, and scaling the install base—priorities that align with FDA-cleared hardware already in clinical use.
Notable leadership hires: Director Strategy Growth, Account Director, Regional Director
Ceribell designs and deploys point-of-care EEG hardware paired with AI algorithms to diagnose and monitor seizures in acute care settings. The Ceribell System is FDA 510(k) cleared and in use across U.S. intensive care units and emergency rooms. The company operates as a medical device manufacturer serving hospital networks, with go-to-market efforts directed at clinical adoption and departmental expansion within existing customer accounts. Pain points center on scaling backend infrastructure, improving penetration in neonatal care, and managing compliance across new hospital launches.
Ceribell manufactures the Ceribell System, an FDA-cleared point-of-care EEG platform combining portable hardware with AI algorithms for rapid seizure detection and neurological monitoring in acute care (ICUs, emergency departments).
Ceribell is headquartered in Sunnyvale, California, and is a publicly traded medical device company founded in 2014 with 201–500 employees.
Other companies in the same industry, closest in size